Stock Analiz

Regeneron Pharmaceuticals, Inc. (REGN) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Regeneron Pharmaceuticals’s revenue went from $4.9B in fiscal 2016 to $14.3B in fiscal 2025, growth of about 12.8% a year.

Net income in fiscal 2025 was $4.5B, a net margin of 31.4%; the best year in this period was 2021 with $8.1B.

Over the twelve months to September 30, 2026, revenue was $16.9B and net income $4.8B.

Free cash flow was $4.1B in fiscal 2025 and positive in 10 of the 10 years shown.

The diluted share count fell 7% over the period (buybacks).

Revenue, profit and cash flow by year

Revenue
2016: $4.9B162017: $5.9B172018: $5.1B182019: $6.6B192020: $8.5B202021: $16.1B212022: $12.2B222023: $13.1B232024: $14.2B242025: $14.3B25$14.3B
Net income
2016: $896M162017: $1.2B172018: $2.4B182019: $2.1B192020: $3.5B202021: $8.1B212022: $4.3B222023: $4.0B232024: $4.4B242025: $4.5B25$4.5B
Free cash flow
2016: $974M162017: $1.0B172018: $1.8B182019: $2.0B192020: $2.0B202021: $6.5B212022: $4.4B222023: $3.9B232024: $3.7B242025: $4.1B25$4.1B
EPS (diluted)
2016: $7.70162017: $10.34172018: $21.29182019: $18.46192020: $30.52202021: $71.97212022: $38.22222023: $34.77232024: $38.34242025: $41.4825$41.48

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$16.9B$14.3B$14.2B$13.1B$12.2B$16.1B$8.5B$6.6B$5.1B$5.9B$4.9B
Gross profit———————$6.2B$4.9B$5.7B$4.7B
Operating income$4.9B$3.6B$4.0B$4.0B$4.7B$8.9B$3.6B$2.2B$2.5B$2.1B$1.3B
Net income$4.8B$4.5B$4.4B$4.0B$4.3B$8.1B$3.5B$2.1B$2.4B$1.2B$896M
EPS (diluted)$45.30$41.48$38.34$34.77$38.22$71.97$30.52$18.46$21.29$10.34$7.70
R&D$6.6B$5.9B$5.1B$4.4B$3.6B$2.9B$2.6B$2.5B$1.5B$2.1B$2.1B
Revenue growth—+1.0%+8.3%+7.8%−24.3%+89.1%+29.6%+27.4%−12.4%+20.8%+18.4%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$4.8B$5.0B$4.4B$4.6B$5.0B$7.1B$2.6B$2.4B$2.2B$1.3B$1.5B
Capital spending-$1.0B-$898M-$756M-$719M-$590M-$552M-$615M-$430M-$383M-$273M-$512M
Free cash flow$3.8B$4.1B$3.7B$3.9B$4.4B$6.5B$2.0B$2.0B$1.8B$1.0B$974M
Dividends paid$383M$370M$0$0———————
Buybacks$3.0B$3.4B$2.6B$2.2B$2.1B$1.6B$5.8B$276M$4M$0$0
Stock-based pay$1.0B$994M$983M$885M$725M$602M$432M$464M$427M$507M$560M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$8.6B$9.0B$10.8B$7.7B$5.7B$3.6B$3.2B$2.8B$1.4B$1.0B
Debt—$2.3B$2.2B$2.1B$2.0B$2.0B$2.0B$24M———
Equity—$31.3B$29.4B$26.0B$22.7B$18.8B$11.0B$11.1B$8.8B$6.1B$4.4B
Total assets—$40.6B$37.8B$33.1B$29.2B$25.4B$17.2B$14.8B$11.7B$8.8B$7.0B
Shares (diluted)106M109M115M114M114M112M115M115M115M116M116M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin———————93.9%95.4%96.5%96.0%
Operating margin28.8%24.9%28.1%30.9%38.9%55.7%42.1%33.7%49.2%35.4%27.4%
Net margin28.5%31.4%31.1%30.1%35.6%50.2%41.3%32.3%47.5%20.4%18.4%
FCF margin22.6%28.4%25.8%29.5%36.4%40.6%23.6%30.5%35.2%17.6%20.0%
ROIC—9.2%11.7%13.6%17.1%37.3%25.4%17.3%27.7%19.5%20.1%
ROE—14.4%15.0%15.2%19.1%43.0%31.9%19.1%27.9%19.5%20.1%

Frequently asked questions

What is Regeneron Pharmaceuticals’s annual revenue?

$14.3B in fiscal 2025 and $16.9B over the twelve months to September 30, 2026.

How much profit does Regeneron Pharmaceuticals make?

Net income was $4.5B in fiscal 2025 (net margin 31.4%).

Is Regeneron Pharmaceuticals’s revenue growing?

Yes: revenue rose 1.0% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.